Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. Its product pipeline consists of AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. The company has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics Inc.

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Akebia Therapeutics today and set a price target of $4.00. According to TipRanks, ...

Piper Sandler Sticks to Their Buy Rating for Akebia Therapeutics (AKBA)

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Akebia Therapeutics, with a price target of $6.00. Cau...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AKBA	$1.42	+2.54%	2.12M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AKBA	$1.42	+2.5%	2.12M
3
4
5
6

AKBA

AKBA

No Data Available

Get Akebia Therapeutics Inc. Data in Excel

Get Akebia Therapeutics Inc. Data in Excel